Actos (pioglitazone)
Title: Actos (pioglitazone)Category: MedicationsCreated: 11/28/1999 12:00:00 AMLast Editorial Review: 9/20/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - September 20, 2016 Category: Endocrinology Source Type: news

3 Drugs with the Most Severe Side Effects
Image Source Drugs have been known to have some sort of side effects on patients. Most of them are not often discussed in the health tabloids. While other drugs have side effects that are very nominal when compared to the benefits the patient derives from their usage, others have side effects that can impact the lives of their users forever. The most common side effects people experience from drug usage are gastrointestinal related issues which include constipation, nausea, and vomiting. Some other drugs can leave you feeling tired and dizzy for a short period of time. Combining these drugs with simple aspirin will usuall...
Source: Healthy Living - The Huffington Post - August 19, 2016 Category: Consumer Health News Source Type: news

Pioglitazone Diabetes Prevention Data Now Published Pioglitazone Diabetes Prevention Data Now Published
Reductions in both cardiovascular events and progression to diabetes suggest that a reexamination of pioglitazone ' s risk/benefit profile may be in order.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 12, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Pioglitazone Improves Fatty Liver in Prediabetes, Diabetes Pioglitazone Improves Fatty Liver in Prediabetes, Diabetes
Results of a single-center randomized trial suggest the drug may halt NASH progression and alter the natural history of the disease. Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 5, 2016 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Pioglitazone effective in diabetes patients with NASH
Pioglitazone may halt the progression of nonalcoholic steatohepatitis in patients with prediabetes or Type 2 diabetes, a randomised trial shows. (Source: MedWire News)
Source: MedWire News - June 27, 2016 Category: Consumer Health News Tags: Diabetes Source Type: news

Long-Term Pioglitazone Use Effective in Patients with NASH and Prediabetes or Diabetes (FREE)
By Atif Zaman, MD, MPH Dr. Zaman is an associate editor with NEJM Journal Watch Gastroenterology, from which this story was adapted. Full coverage is available to subscribers at the link below.Pioglitazone is associated with improved disease activity in patients with nonalcoholic steatohepatitis (NASH) plus prediabetes or … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 20, 2016 Category: Primary Care Source Type: news

Pioglitazone safe and effective for steatohepatitis in T2DM
Long-term pioglitazone is not only safe for patients with nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes but is associated with significant improvements in fatty liver disease... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 20, 2016 Category: Endocrinology Source Type: news

Pioglitazone Slows Progression to Type 2 Diabetes: More IRIS DataPioglitazone Slows Progression to Type 2 Diabetes: More IRIS Data
New and previously reported data from the IRIS trial prompt discussion of reevaluating the role of now-generic pioglitazone in the treatment and prevention of diabetes and stroke. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 17, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Actos After Stroke May Prevent Diabetes (CME/CE)
(MedPage Today) -- Treatment appears to stop progression from pre-diabetes (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 15, 2016 Category: Cardiology Source Type: news

FDA Follies, Part 2
Part 1 of this series appeared just over a year ago (in a different publication), and detailed a few of the agency's recent missteps. Prominently mentioned was the sad case of certain diabetes meds, including Actos, once touted as a safer alternative to Avandia. Avandia was taken off the market in 2011, but reappeared subject to severe limitations of use. These limitations were later removed—although current usage of the drug is small. Oddly, Actos (FDA approved in July, 1999) was showing some problems (bladder cancer) as early as 2005, even though this information was not widely disseminated at the time. Some...
Source: Healthy Living - The Huffington Post - May 17, 2016 Category: Consumer Health News Source Type: news

Is the Diabetes 'Holy Grail' in Reach?Is the Diabetes 'Holy Grail' in Reach?
With empagliflozin, pioglitazone, and liraglutide, we may finally be getting closer to the 'holy grail' of a diabetes drug that also has cardiovascular benefits. Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 11, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news

Diabetes drug pioglitazone could get personal: Neither panacea, nor peril
When I was in training, one of my beloved mentors declared, “I never use a drug until it’s been on the market for 20 years.” I was young enough then that I couldn’t fathom being a doctor for 20 years, let alone waiting two decades to use a new drug. As my career has progressed, I’ve seen many new drugs released to the market. Some of them are truly miraculous, bringing people longer, healthier, and more productive lives. Many of them have not withstood the test of time. More than a few have even been taken off the market. Even though the Food and Drug Administration diligently reviews each new medicine before it...
Source: New Harvard Health Information - May 5, 2016 Category: Consumer Health News Authors: Lori Wiviott Tishler, MD, MPH Tags: Diabetes Drugs and Supplements pioglitazone thiazolidinediones Source Type: news

Pioglitazone Use and Risk of Bladder CancerPioglitazone Use and Risk of Bladder Cancer
The results of this large population based study indicate that pioglitazone is associated with an increased risk of bladder cancer. But is it drug specific, or a class effect? British Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Elevated bladder cancer risk with pioglitazone use
Use of the antidiabetic drug pioglitazone is linked to an increased risk of developing bladder cancer, with the risk rising with increasing duration of use and dose, say Canadian researchers. (Source: MedWire News)
Source: MedWire News - April 5, 2016 Category: Consumer Health News Tags: Oncology Source Type: news

FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer
[6-15-2011] The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 1, 2016 Category: Drugs & Pharmacology Source Type: news